HMOX1 and cardiovascular disorder: Treatment with phosphocreatine prevented cardiovascular disease through modulating the creatine kinase/phosphocreatine energy buffer and transport system [26,27] and inhibited kidney injury via the regulation of the ERK/Nrf2/HO-1 signaling pathway [28].